Trial Outcomes & Findings for PillCam™ Colon Capsule Endoscopy (PCCE) in the Visualization of the Colon (NCT NCT00604162)
NCT ID: NCT00604162
Last Updated: 2019-08-01
Results Overview
The number of participants that completed the capsule endoscopy procedure with video images of the entire colon that could be read by a clinician, or subsequently had a full colonoscopy with visualization by a different clinician. The number of successful procedures of each type are reported.
COMPLETED
PHASE3
332 participants
1 day
2019-08-01
Participant Flow
8 Hospital sites
Four patients withdrew before completing the study documents and were not included in the analysis.An additional 8 patients were not included in the analysis of the accuracy of polyp detection.
Participant milestones
| Measure |
Colon Capsule Endoscopy, Then Standard Colonoscopy
Capsule endoscopy was ingested following colon preparation without colon insufflation or sedation.The purpose was to detect patients with polyps equal or larger than 6mm. Patients subsequently had standard colonoscopy as "gold standard" comparison.
|
|---|---|
|
Overall Study
STARTED
|
332
|
|
Overall Study
COMPLETED
|
328
|
|
Overall Study
NOT COMPLETED
|
4
|
Reasons for withdrawal
| Measure |
Colon Capsule Endoscopy, Then Standard Colonoscopy
Capsule endoscopy was ingested following colon preparation without colon insufflation or sedation.The purpose was to detect patients with polyps equal or larger than 6mm. Patients subsequently had standard colonoscopy as "gold standard" comparison.
|
|---|---|
|
Overall Study
Physician Decision
|
3
|
|
Overall Study
Withdrawal by Subject
|
1
|
Baseline Characteristics
PillCam™ Colon Capsule Endoscopy (PCCE) in the Visualization of the Colon
Baseline characteristics by cohort
| Measure |
Colon Capsule Endoscopy, Then Standard Colonoscopy
n=328 Participants
Capsule endoscopy was ingested following colon preparation without colon insufflation or sedation.The purpose was to detect patients with polyps equal or larger than 6mm. Patients subsequently had standard colonoscopy as "gold standard" comparison.
|
|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=99 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
227 Participants
n=99 Participants
|
|
Age, Categorical
>=65 years
|
101 Participants
n=99 Participants
|
|
Age, Continuous
|
58.5 years
STANDARD_DEVIATION 12.1 • n=99 Participants
|
|
Sex: Female, Male
Female
|
147 Participants
n=99 Participants
|
|
Sex: Female, Male
Male
|
181 Participants
n=99 Participants
|
|
Region of Enrollment
France
|
96 participants
n=99 Participants
|
|
Region of Enrollment
Spain
|
63 participants
n=99 Participants
|
|
Region of Enrollment
Germany
|
49 participants
n=99 Participants
|
|
Region of Enrollment
Italy
|
53 participants
n=99 Participants
|
|
Region of Enrollment
United Kingdom
|
20 participants
n=99 Participants
|
|
Region of Enrollment
Belgium
|
47 participants
n=99 Participants
|
PRIMARY outcome
Timeframe: 1 dayThe number of participants that completed the capsule endoscopy procedure with video images of the entire colon that could be read by a clinician, or subsequently had a full colonoscopy with visualization by a different clinician. The number of successful procedures of each type are reported.
Outcome measures
| Measure |
PillCam COLON
n=328 Participants
Ingestible capsule equipped with an endoscope with two imagers, given after bowel preparation and before standard colonoscopy.
|
Standard Colonoscopy
n=328 Participants
After bowel preparation and capsule endoscopy, patients subsequently had standard colonoscopy as "gold standard" comparison (with colon insufflation and sedation).
|
|---|---|---|
|
Number of Participants With Successful Capsule Endoscopies or Standard Colonoscopies
|
322 participants
|
326 participants
|
PRIMARY outcome
Timeframe: 1 dayPopulation: Participants in the Accuracy Analysis successfully had both capsule endoscopy and colonoscopy.
Since the standard colonoscopy is the "gold standard" to which the PillCam is to be compared, the number of participants with the indicated lesions identified by a trained clinician using standard colonoscopy procedures is reported here. Note that some Participants had multiple lesions and so could be included in more than one size category. Advanced adenoma is defined as 1) an adenoma 1 cm or larger or 2) an adenoma with villous features or high-grade dysplasia. All colorectal cancers were 6mm or larger.
Outcome measures
| Measure |
PillCam COLON
n=320 Participants
Ingestible capsule equipped with an endoscope with two imagers, given after bowel preparation and before standard colonoscopy.
|
Standard Colonoscopy
After bowel preparation and capsule endoscopy, patients subsequently had standard colonoscopy as "gold standard" comparison (with colon insufflation and sedation).
|
|---|---|---|
|
Number of Participants With Indicated Lesions Detected by Standard Colonoscopy
Polyp, Any Size
|
212 participants
Interval 66.0 to 77.0
|
—
|
|
Number of Participants With Indicated Lesions Detected by Standard Colonoscopy
Polyp, < 6 mm
|
188 participants
|
—
|
|
Number of Participants With Indicated Lesions Detected by Standard Colonoscopy
Polyp, >= 6 mm
|
87 participants
|
—
|
|
Number of Participants With Indicated Lesions Detected by Standard Colonoscopy
Polyp, >= 10 mm
|
50 participants
|
—
|
|
Number of Participants With Indicated Lesions Detected by Standard Colonoscopy
Adenoma, >= 6 mm
|
71 participants
|
—
|
|
Number of Participants With Indicated Lesions Detected by Standard Colonoscopy
Adenoma, >= 10 mm
|
45 participants
|
—
|
|
Number of Participants With Indicated Lesions Detected by Standard Colonoscopy
Advanced Adenoma, Any Size
|
52 participants
|
—
|
|
Number of Participants With Indicated Lesions Detected by Standard Colonoscopy
Advanced Adenoma, >= 6 mm
|
49 participants
|
—
|
|
Number of Participants With Indicated Lesions Detected by Standard Colonoscopy
Advanced Adenoma, >= 10 mm
|
45 participants
|
—
|
|
Number of Participants With Indicated Lesions Detected by Standard Colonoscopy
Colorectal Cancer
|
19 participants
|
—
|
PRIMARY outcome
Timeframe: 1 dayPopulation: Accuracy Analysis population had both successful capsule endoscopy and colonoscopy.
Readings of videos from the PillCam COLON were performed by trained physicians who identified lesions (types and sizes). Sensitivity was calculated as the percentage of participants who had positive findings on capsule endoscopy (of a specified category) among those participants who had positive findings on colonoscopy of the same category (reported in Outcome Measure 1). The false negative rate is equal to 1 - sensitivity and indicated the percentage of lesions missed by capsule endoscopy.
Outcome measures
| Measure |
PillCam COLON
n=320 Participants
Ingestible capsule equipped with an endoscope with two imagers, given after bowel preparation and before standard colonoscopy.
|
Standard Colonoscopy
After bowel preparation and capsule endoscopy, patients subsequently had standard colonoscopy as "gold standard" comparison (with colon insufflation and sedation).
|
|---|---|---|
|
Sensitivity of Capsule Endoscopy for Indicated Lesions
Polyp, Any Size (n=212)
|
72 Percentage of Participants
Interval 68.0 to 75.0
|
—
|
|
Sensitivity of Capsule Endoscopy for Indicated Lesions
Polyp, < 6 mm (n=188)
|
61 Percentage of Participants
Interval 57.0 to 64.0
|
—
|
|
Sensitivity of Capsule Endoscopy for Indicated Lesions
Polyp, >= 6 mm (n=87)
|
64 Percentage of Participants
Interval 59.0 to 72.0
|
—
|
|
Sensitivity of Capsule Endoscopy for Indicated Lesions
Polyp, >= 10 mm (n=50)
|
60 Percentage of Participants
Interval 51.0 to 66.0
|
—
|
|
Sensitivity of Capsule Endoscopy for Indicated Lesions
Adenoma, >= 6 mm (n=71)
|
68 Percentage of Participants
Interval 58.0 to 76.0
|
—
|
|
Sensitivity of Capsule Endoscopy for Indicated Lesions
Adenoma, >= 10 mm (n=45)
|
64 Percentage of Participants
Interval 54.0 to 72.0
|
—
|
|
Sensitivity of Capsule Endoscopy for Indicated Lesions
Advanced Adenoma, Any Size (n=52)
|
85 Percentage of Participants
Interval 73.0 to 93.0
|
—
|
|
Sensitivity of Capsule Endoscopy for Indicated Lesions
Advanced Adenoma, >= 6 mm (n=49)
|
73 Percentage of Participants
Interval 61.0 to 83.0
|
—
|
|
Sensitivity of Capsule Endoscopy for Indicated Lesions
Advanced Adenoma, >= 10 mm (n=45)
|
64 Percentage of Participants
Interval 54.0 to 72.0
|
—
|
|
Sensitivity of Capsule Endoscopy for Indicated Lesions
Colorectal Cancer (n=19)
|
74 Percentage of Participants
Interval 52.0 to 88.0
|
—
|
PRIMARY outcome
Timeframe: 1 dayPopulation: Accuracy Analysis population had both successful capsule endoscopy and colonoscopy.
Readings of videos from the PillCam COLON were performed by trained physicians who identified lesions (types and sizes). Specificity was calculated as the percentage of participants who had negative findings on capsule endoscopy (of a specified category) among participants with negative colonoscopy findings of the same category (reported in Outcome Measure 1). This corresponds to 1 - the false positive rate.
Outcome measures
| Measure |
PillCam COLON
n=320 Participants
Ingestible capsule equipped with an endoscope with two imagers, given after bowel preparation and before standard colonoscopy.
|
Standard Colonoscopy
After bowel preparation and capsule endoscopy, patients subsequently had standard colonoscopy as "gold standard" comparison (with colon insufflation and sedation).
|
|---|---|---|
|
Specificity of Capsule Endoscopy for Indicated Lesions
Polyp, Any Size (n=108)
|
78 Percentage of Participants
Interval 71.0 to 84.0
|
—
|
|
Specificity of Capsule Endoscopy for Indicated Lesions
Polyp, < 6 mm (n=132)
|
82 Percentage of Participants
Interval 76.0 to 87.0
|
—
|
|
Specificity of Capsule Endoscopy for Indicated Lesions
Polyp, >= 6 mm (n=233)
|
84 Percentage of Participants
Interval 81.0 to 87.0
|
—
|
|
Specificity of Capsule Endoscopy for Indicated Lesions
Polyp, >= 10 mm (n=270)
|
98 Percentage of Participants
Interval 96.0 to 99.0
|
—
|
|
Specificity of Capsule Endoscopy for Indicated Lesions
Adenoma, >= 6 mm (n=249)
|
82 Percentage of Participants
Interval 79.0 to 84.0
|
—
|
|
Specificity of Capsule Endoscopy for Indicated Lesions
Adenoma, >= 10 mm (n=275)
|
97 Percentage of Participants
Interval 96.0 to 99.0
|
—
|
|
Specificity of Capsule Endoscopy for Indicated Lesions
Advanced Adenoma, Any Size (n=268)
|
50 Percentage of Participants
Interval 48.0 to 51.0
|
—
|
|
Specificity of Capsule Endoscopy for Indicated Lesions
Advanced Adenoma, >= 6 mm (n=271)
|
79 Percentage of Participants
Interval 77.0 to 81.0
|
—
|
|
Specificity of Capsule Endoscopy for Indicated Lesions
Advanced Adenoma, >= 10 mm (n=275)
|
97 Percentage of Participants
Interval 96.0 to 99.0
|
—
|
|
Specificity of Capsule Endoscopy for Indicated Lesions
Colorectal Cancer (n=301)
|
74 Percentage of Participants
Interval 72.0 to 75.0
|
—
|
SECONDARY outcome
Timeframe: 1 dayOverall colon cleanliness was judged for capsule endoscopy and colonoscopy on a four-point grading index scale as follows: 1. poor cleansing level (Large amount of fecal residue.) 2. fair cleansing level (Enough feces or dark fluid present to preclude a completely reliable examination.) 3. good cleansing level (Small amount of feces or dark fluid, but not enough to interfere with examination.) 4. excellent cleansing level (No more than small bits of adherent feces.)
Outcome measures
| Measure |
PillCam COLON
n=320 Participants
Ingestible capsule equipped with an endoscope with two imagers, given after bowel preparation and before standard colonoscopy.
|
Standard Colonoscopy
n=320 Participants
After bowel preparation and capsule endoscopy, patients subsequently had standard colonoscopy as "gold standard" comparison (with colon insufflation and sedation).
|
|---|---|---|
|
Percent of Participants With Scoring Index 3 or 4
|
72 Percentage of Participants
Interval 66.0 to 77.0
|
87 Percentage of Participants
Interval 83.0 to 91.0
|
SECONDARY outcome
Timeframe: Within 7 daysOutcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: within 7 daysOutcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: Within 7 daysOutcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: within 7 daysOutcome measures
Outcome data not reported
Adverse Events
Adverse Events Related to Colonoscopy
Adverse Events Related to the Capsule
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place